These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 31506873)

  • 1. Absorption, Distribution, and Binding Profile of ME-401, a Potent and Selective Oral Small-Molecule Inhibitor of Phosphatidylinositol 3-Kinase δ (PI3Kδ) in Animal and B-Cell Lymphoma Models.
    Moreno O; Wood J
    Target Oncol; 2019 Oct; 14(5):603-611. PubMed ID: 31506873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
    Ma X; Wei J; Wang C; Gu D; Hu Y; Sheng R
    Eur J Med Chem; 2019 May; 170():112-125. PubMed ID: 30878826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
    Salphati L; Pang J; Plise EG; Lee LB; Olivero AG; Prior WW; Sampath D; Wong S; Zhang X
    Drug Metab Dispos; 2012 Sep; 40(9):1785-96. PubMed ID: 22696419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly selective PI3Kδ inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon.
    Yang X; Bai H; Yuan X; Yang X; Liu Y; Guo M; Hu N; Jiang B; Lian Z; Ma Z; Wang J; Sun X; Zhang T; Su D; Wu Y; Li J; Wang F; Wang Z; Wang L; Liu X; Song X
    Neoplasia; 2024 Nov; 57():101053. PubMed ID: 39260132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SHC014748M, a novel selective inhi-bitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B cell lymphomas and chronic lymphocytic leukemia.
    Fan L; Wang C; Zhao L; Wang Z; Zhang X; Liu X; Cao L; Xu W; Li J
    Neoplasia; 2020 Dec; 22(12):714-724. PubMed ID: 33142237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of AS2541019, a novel selective PI3Kδ inhibitor, on antibody production and hamster to rat xenotransplantation.
    Marui T; Fukahori H; Kawashima T; Ito M; Akamatsu M; Kaneko Y; Takahashi F; Imada S; Morokata T
    Eur J Pharmacol; 2018 May; 826():179-186. PubMed ID: 29518396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAR study of 5-alkynyl substituted quinazolin-4(3H)-ones as phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
    Wei M; Zhang X; Wang X; Song Z; Ding J; Meng LH; Zhang A
    Eur J Med Chem; 2017 Jan; 125():1156-1171. PubMed ID: 27846451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Optimization of Thienopyrimidine Derivatives as Potent and Selective PI3Kδ Inhibitors for the Treatment of B-Cell Malignancies.
    Zhang J; Jiang H; Lin S; Wu D; Tian H; Jiang L; Cui Y; Jin J; Chen X; Xu H
    J Med Chem; 2022 Jun; 65(11):8011-8028. PubMed ID: 35609190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell lymphomas.
    Lou SY; Zheng FL; Tang YM; Zheng YN; Lu J; An H; Zhang EJ; Cui SL; Zhao HJ
    Life Sci; 2024 Jun; 347():122662. PubMed ID: 38670450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a Potent and Selective PI3Kδ Inhibitor (
    Shukla MR; Patra S; Verma M; Sadasivam G; Jana N; Mahangare SJ; Vidhate P; Lagad D; Tarage A; Cheemala M; Kulkarni C; Bhagwat S; Chaudhari VD; Sayyed M; Pachpute V; Phadtare R; Gole G; Phukan S; Sunkara B; Samant C; Shingare M; Naik A; Trivedi S; Marisetti AK; Reddy M; Gholve M; Mahajan N; Sabde S; Patil V; Modi D; Mehta M; Nigade P; Tamane K; Tota S; Goyal H; Volam H; Pawar S; Ahirrao P; Dinchhana L; Mallurwar S; Akarte A; Bokare A; Kanhere R; Reddy N; Koul S; Dandekar M; Singh M; Bernstein PR; Narasimham L; Bhonde M; Gundu J; Goel R; Kulkarni S; Sharma S; Kamboj RK; Palle VP
    J Med Chem; 2020 Dec; 63(23):14700-14723. PubMed ID: 33297683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. INCB040093 Is a Novel PI3K
    Shin N; Li YL; Mei S; Wang KH; Hall L; Katiyar K; Wang Q; Yang G; Rumberger B; Leffet L; He X; Rupar M; Bowman K; Favata M; Li J; Liu M; Li Y; Covington M; Koblish H; Soloviev M; Shuey D; Burn T; Diamond S; Fridman J; Combs A; Yao W; Yeleswaram S; Hollis G; Vaddi K; Huber R; Newton R; Scherle P
    J Pharmacol Exp Ther; 2018 Jan; 364(1):120-130. PubMed ID: 29127109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAF-248, a novel PI3Kδ-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma.
    Zhang X; Duan YT; Wang Y; Zhao XD; Sun YM; Lin DZ; Chen Y; Wang YX; Zhou ZW; Liu YX; Jiang LH; Geng MY; Ding J; Meng LH
    Acta Pharmacol Sin; 2022 Jan; 43(1):209-219. PubMed ID: 33782541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase
    Shin N; Stubbs M; Koblish H; Yue EW; Soloviev M; Douty B; Wang KH; Wang Q; Gao M; Feldman P; Yang G; Hall L; Hansbury M; O'Connor S; Leffet L; Collins R; Katiyar K; He X; Waeltz P; Collier P; Lu J; Li YL; Li Y; Liu PCC; Burn T; Covington M; Diamond S; Shuey D; Roberts A; Yeleswaram S; Hollis G; Metcalf B; Yao W; Huber R; Combs A; Newton R; Scherle P
    J Pharmacol Exp Ther; 2020 Jul; 374(1):211-222. PubMed ID: 32345620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.